328 related articles for article (PubMed ID: 2925225)
1. Inhibition of immune haemolysis by a serum factor found in C3-deficient subjects.
Kitamura H; Tsuboi M
Immunology; 1989 Feb; 66(2):264-9. PubMed ID: 2925225
[TBL] [Abstract][Full Text] [Related]
2. C3-independent immune haemolysis: mechanism of membrane attack complex formation.
Kitamura H; Tsuboi M; Nagaki K
Immunology; 1986 Sep; 59(1):147-51. PubMed ID: 3759127
[TBL] [Abstract][Full Text] [Related]
3. Trypsin-activated complex of human factor B with cobra venom factor (CVF), cleaving C3 and C5 and generating a lytic factor for unsensitized guinea pig erythrocytes. I. Generation of the activated complex.
Miyama A; Kato T; Horai S; Yokoo J; Kashiba S
Biken J; 1975 Dec; 18(4):193-204. PubMed ID: 1218074
[TBL] [Abstract][Full Text] [Related]
4. Activation of the fifth and sixth component of the complement system: similarities between C5b6 and C(56)a with respect to lytic enhancement by cell-bound C3b or A2C, and species preferences of target cell.
Hänsch GM; Hammer CH; Mayer MM; Shin ML
J Immunol; 1981 Sep; 127(3):999-1002. PubMed ID: 6911149
[TBL] [Abstract][Full Text] [Related]
5. The activation of C5 in the fluid phase and in the absence of C3 through the classical pathway of the complement system.
Kitamura H; Tsuboi M; Nagaki K
Immunology; 1986 Jul; 58(3):459-65. PubMed ID: 3733147
[TBL] [Abstract][Full Text] [Related]
6. C3-independent immune haemolysis: haemolysis of EAC14oxy2 cells by C5-C9 without participation of C3.
Kitamura H; Matsumoto M; Nagaki K
Immunology; 1984 Nov; 53(3):575-82. PubMed ID: 6237987
[TBL] [Abstract][Full Text] [Related]
7. Cyanate as an inactivator of complement proteins.
Schultz DR; Arnold PI
J Immunol; 1975 Dec; 115(6):1558-65. PubMed ID: 1184967
[TBL] [Abstract][Full Text] [Related]
8. Lytic activity of C5-9 complexes for erythrocytes from the species other than sheep: C9 rather than C8-dependent variation in lytic activity.
Yamamoto KI
J Immunol; 1977 Oct; 119(4):1482-5. PubMed ID: 894048
[TBL] [Abstract][Full Text] [Related]
9. Complement lysis of human erythrocytes. Differeing susceptibility of two types of paroxysmal nocturnal hemoglobinuria cells to C5b-9.
Packman CH; Rosenfeld SI; Jenkins DE; Thiem PA; Leddy JP
J Clin Invest; 1979 Aug; 64(2):428-33. PubMed ID: 457861
[TBL] [Abstract][Full Text] [Related]
10. Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9.
Shin ML; Hänsch G; Hu VW; Nicholson-Weller A
J Immunol; 1986 Mar; 136(5):1777-82. PubMed ID: 2419414
[TBL] [Abstract][Full Text] [Related]
11. Role of TraT protein, an anticomplementary protein produced in Escherichia coli by R100 factor, in serum resistance.
Pramoonjago P; Kaneko M; Kinoshita T; Ohtsubo E; Takeda J; Hong KS; Inagi R; Inoue K
J Immunol; 1992 Feb; 148(3):827-36. PubMed ID: 1730875
[TBL] [Abstract][Full Text] [Related]
12. Study on C3-like factor in the serum of a C3-deficient subject.
Kitamura H; Nishimukai H; Sano Y; Nagaki K
Immunology; 1984 Feb; 51(2):239-45. PubMed ID: 6693133
[TBL] [Abstract][Full Text] [Related]
13. An anticomplementary agent, K-76 monocarboxylic acid: its site and mechanism of inhibition of the complement activation cascade.
Hong K; Kinoshita T; Miyazaki W; Izawa T; Inoue K
J Immunol; 1979 Jun; 122(6):2418-23. PubMed ID: 448130
[TBL] [Abstract][Full Text] [Related]
14. Testing of hemolytic complement components in domestic animals.
Barta O; Hubbert NL
Am J Vet Res; 1978 Aug; 39(8):1303-8. PubMed ID: 697137
[TBL] [Abstract][Full Text] [Related]
15. Homologous species restriction in lysis of erythrocytes by terminal complement proteins.
Hänsch GM; Hammer CH; Vanguri P; Shin ML
Proc Natl Acad Sci U S A; 1981 Aug; 78(8):5118-21. PubMed ID: 6946459
[TBL] [Abstract][Full Text] [Related]
16. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve increased C7 binding or cell-bound C3b.
Rosenfeld SI; Jenkins DE; Leddy JP
J Immunol; 1985 Jan; 134(1):506-11. PubMed ID: 3964820
[TBL] [Abstract][Full Text] [Related]
17. The functional significance of complement.
Fearon DT; Ruddy S; Knostman JD; Carpenter CB; Austen KF
Adv Nephrol Necker Hosp; 1974; 4():15-35. PubMed ID: 4219991
[No Abstract] [Full Text] [Related]
18. Electrophoresis of guinea-pig complement components (C3, C5, C6, C7, C8 and C9) on polyacrylamide gel.
Okada H; Mayumi M; Mukojima T; Sekine T; Torisu M
Immunology; 1970 Apr; 18(4):493-500. PubMed ID: 5421032
[TBL] [Abstract][Full Text] [Related]
19. The attack phase of human complement: differentiation between membrane binding and complex formation by the detection of neoantigen expression in situ. A morphometric immunoferritin study.
Balkarowa-Ständer J; Rother U; Rauterberg EW
J Immunol; 1981 Sep; 127(3):1089-93. PubMed ID: 7264298
[TBL] [Abstract][Full Text] [Related]
20. Isolation and characterization of a low molecular weight complement inhibitor present in normal human serum.
Baker PJ; Osofsky SG
Clin Exp Immunol; 1981 Mar; 43(3):549-56. PubMed ID: 6912799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
